Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    134
    ...
ATC Name B/G Ingredients Dosage Form Price
J01CR05 YANOVEN G Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g Injectable powder for solution 10,860,623 L.L
J01MA02 ESTECINA 500MG G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 618,168 L.L
L02BG03 ANASTROZOL GP PHARM G Anastrozole - 1mg 1mg Tablet, film coated 1,181,238 L.L
M01AB05 DOLONIL G Diclofenac sodium - 75mg/3ml 75mg/3ml Injectable solution 3,801,155 L.L
N01AH01 FENTANYL MEDIS G Fentanyl (citrate) - 0.5mg/10ml 0.5mg/10ml Injectable solution 1,190,644 L.L
N03AF02 HARMONIE G Oxcarbazepine - 300mg 300mg Tablet, film coated 889,496 L.L
N05AX12 JOSWE ARIPAL 5 G Aripiprazole - 5mg 5mg Tablet 1,389,533 L.L
N07CA02 CINNARIZINE G Cinnarizine - 75mg 75mg Capsule 386,515 L.L
R05CB03 MUCOTAL PEDIATRIQUE G Carbocysteine - 100mg/5ml 100mg/5ml Syrup 298,205 L.L
M05BA08 ZOLEDRO-DENK G Zoledronic acid - 4mg/5ml 4mg/5ml Injectable concentrate for solution L.L
A02BX02 SUCRATE GEL G Sucralfate - 1g 1g Gel 636,981 L.L
A11CC06 DEDROGYL G Calcifediol - 15mg/100ml 15mg/100ml Drops solution 827,807 L.L
B03BA01 COBAL G Vitamin B12 - 500mcg 500mcg Tablet, coated 486,471 L.L
C09CA06 ARKANDA 16 G Candesartan cilexetil - 16mg 16mg Tablet 639,925 L.L
C10AA07 ROVASTIN G Rosuvastatin (calcium) - 20mg 20mg Tablet 560,574 L.L
G04BE08 TADALAFIL BIOGARAN G Tadalafil - 10mg 10mg Tablet, coated 1,397,596 L.L
J01CR50 FLUMOX G Flucloxacillin (monohydrate) - 250mg, Amoxicillin (trihydrate) - 250mg Capsule 348,055 L.L
J01MA02 LADININ G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 595,060 L.L
J07AH MENFIVE G Meningococcal (serogroups A, C, Y, W, X) Polysaccharide conjugate vaccine - Injectable freeze dried powder + diluent 3,527,587 L.L
L02BG03 ANASTROZOLE ARROW LAB G Anastrozole - 1mg 1mg Tablet 1,552,138 L.L
M01AB05 OLFEN 75MG G Diclofenac sodium - 75mg 75mg Injectable solution 307,740 L.L
N01AH01 FENTANYL PANPHARMA G Fentanyl - 0.5mg/10ml 0.5mg/10ml Injectable solution 1,243,054 L.L
N05AX12 PIRIFY G Aripiprazole - 5mg 5mg Tablet 614,328 L.L
N07CA03 ZINASEN G Flunarizine (HCl) - 10mg 10mg Tablet 591,291 L.L
R05CB03 MUCOTAL ADULTE G Carbocysteine - 250mg/5ml 250mg/5ml Syrup 308,444 L.L
L04AA06 IMUNOCELL G Mycophenolate mofetil - 500mg 500mg Tablet, film coated L.L
B03BA01 CYNOVIT-JULPHAR G Vitamin B12 - 1mg/ml 1mg/ml Injectable solution 167,980 L.L
C09CA06 CANDESARTAN BIOGARAN G Candesartan cilexetil - 16mg 16mg Tablet, scored 434,061 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 749,058 L.L
D10AF02 MED-ERYTHROMYCIN 4% G Erythromycin - 40mg/ml 4% Solution 235,492 L.L
    ...
    134
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026